Esteato-hepatite não alcoólica: uma síndrome em evidência / Non-Alcoholic Steatohepatitis: a syndrome in evidence

Isabelle Meneses da Ponte, Matheus Eugênio de Sousa Lima, Matheus Couto Furtado Albuquerque, Ana Flávia de Holanda Veloso, Tatiana Paschoalette Rodrigues Bachur

Abstract


O presente artigo apresenta uma revisão narrativa sobre epidemiologia, fisiopatologia, diagnóstico e tratamento da esteato-hepatite não alcóolica (EHNA). Nas últimas décadas, houve um crescimento na incidência mundial de obesidade e de doenças associadas. Dentre elas, destaca-se a EHNA, uma desordem metabólica com ampla variedade de apresentação, parte do espectro da doença hepática gordurosa não-alcóolica (DHGNA). A prevalência da DHGNA pode acometer até 25% da população em alguns estudos, sendo homens e hispânicos os grupos mais acometidos. A fisiopatologia da doença é complexa e multifatorial, com bases na obesidade, na resistência à insulina e na herança genética. Após diagnóstico, o manejo da EHNA consiste principalmente em mudanças de estilo de vida, tratamento da síndrome metabólica, farmacoterapia e manejo das complicações da cirrose hepática. Diante do aumento na prevalência de EHNA, é de grande interesse para a medicina a busca por melhores formas de obter sua detecção precoce, tratamento e controle de complicações. Essas questões são complexas e exigem uma abordagem multidisciplinar.


Keywords


Doença hepática gordurosa não alcoólica; esteato-hepatite não alcóolica; obesidade; hepatologia; medicina interna; fígado gorduroso.

References


Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434-8.

Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol. 2014;20(36):12956-80.

http://doi.org/10.3748/wjg.v20.i36.12956

Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci. 2005;50(1):171-80.

Araújo AR, Rosso N, Bedogni G, Tiribelli C, Bellentani S. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future. Liver Int. 2018;38(Suppl 1):47-51.

http://doi.org/10.1111/liv.13643

Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol. 2014;6(5):274-83.

http://doi.org/10.4254/wjh.v6.i5.274

Gelfand JA, Callahan MV. Fever of unknown origin. In: Longo DL, Fauci A, Kasper D, Hauser S, Jameson JL, Loscalzo J. Harrison’s principles of internal medicine. Vol. 1 and 2. 18th edition. McGraw-Hill, 2012; p.158-64.

Angulo P, Lindor KD. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-31.

http://doi.org/10.1056/NEJMra011775

Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686-90.

http://doi.org/10.1038/nrgastro.2013.171

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. http://doi.org/10.1002/hep.28431

Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-85.

http://doi.org/10.1111/j.1365-2036.2011.04724.x

Liu K, McCaughan GW. Epidemiology and etiologic associations of non-alcoholic fatty liver disease and associated HCC. Adv Exp Med Biol. 2018;1061:3-18. http://doi.org/10.1007/978-981-10-8684-7_2

Chen Z, Chen L, Dai H, Chen J, Fang L. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B. 2008;9(8):616-22.

http://doi.org/10.1631/jzus.B0720016

Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S, et al. Nonalcoholic fatty liver disease and aging: epidemiology to management. World J Gastroenterol. 2014;20(39):14185-204.

http://doi.org/10.3748/wjg.v20.i39.14185

Stål P. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World J Gastroenterol. 2015;21(39):11077-87. http://doi.org/10.3748/wjg.v21.i39.11077

Erickson SK. Nonalcoholic fatty liver disease. J Lipid Res. 2009;50(Suppl):S412-6. http://doi.org/10.1194/jlr.R800089-JLR200

Caldwell SH, Ikura Y, Iezzoni JC, Liu Z. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)? J Gastroenterol Hepatol. 2007;22(Suppl 1):S11-9.

http://doi.org/10.1111/j.1440-1746.2006.04639.x

Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461-5.

http://doi.org/10.1038/ng.257

Pang Q, Zhang JY, Song SD, Qu K, Xu XS, Liu SS, et al. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. World J Gastroenterol. 2015;21(5):1650-62.

http://doi.org/10.3748/wjg.v21.i5.1650

Wong VWS, Chu WCW, Wong GLH, Chan RSM, Chim AML, Ong A, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2012;61(3):409-15.

http://doi.org/10.1136/gutjnl-2011-300342

Petta S, Gastaldelli A, Rebelos E, Bugianesi E, Messa P, Miele L, et al. Pathophysiology of non alcoholic fatty liver disease. Int J Mol Sci. 2016;17(12):2082. http://doi.org/10.3390/ijms17122082

Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013;10(11):627-36.

http://doi.org/10.1038/nrgastro.2013.149

Hübscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology. 2006;49(5):450-65.

http://doi.org/10.1111/j.1365-2559.2006.02416.x

Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387-95.

http://doi.org/10.1002/hep.20466

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, Hepatology. 2018; 67(1):329-57.

http://doi.org/10.1002/hep.29367

Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol. 2013;58(5):1007-19.

http://doi.org/10.1016/j.jhep.2012.11.021

Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol. 2011;21(1):87-97.

http://doi.org/10.1007/s00330-010-1905-5

Tannapfel A, Dienes HP, Lohse AW. The indications for liver biopsy. Dtsch Arztebl Int. 2012;109(27-28):477-83.

http://doi.org/10.3238/arztebl.2012.0477

Consenso da Sociedade Brasileira de Hepatologia. Doença hepática gordurosa não alcoólica. Disponível em:

http://www.sbhepatologia.org.br/pdf/Consenso_DHGNA_da_SBH-2015.pdf. Acesso em: 12 maio 2019.

Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factor. Hepatology. 1990;12(5)1106-10. https://doi.org/10.1002/hep.1840120505

Lim LG, Cheng CL, Wee A, Lim SG, Lee YM, Sutedja DS, et al. Prevalence and clinical associations of posttransplant fatty liver disease. Liver Int. 2007;27(1):76-80.

https://doi.org/10.1111/j.1478-3231.2006.01396.x

Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol. 2014;5(4):277-86.

https://doi.org/10.1136/flgastro-2013-100404

Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121-9.

https://doi.org/10.1002/hep.23276

Abenavoli L, Greco M, Milic N, Accattato F, Foti D, Gulletta E, et al. Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: a randomized study. Nutrients. 2017;9(8):E870.

https://doi.org/10.3390/nu9080870

Gelli C, Tarocchi M, Abenavoli L, Di Renzo L, Galli A, Lorenzo A. Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease. World J Gastroenterol. 2017;23(17):3150-62.

https://doi.org/10.3748/wjg.v23.i17.3150

Younossi ZM, Stepanova M, Ong J, Yilmaz Y, Duseja A, Eguchi Y, et al. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients with Non-alcoholic and Alcohol-Related Fatty Liver Disease. Clinical Gastroenterology and Hepatology. 2018.

https://doi.org/10.1016/j.cgh.2018.11.033

Lira CT, Santos MA, Gomes PP, Fidelix YL, Santos AC, Tenório TR, et al. Aerobic training performed at ventilatory threshold improves liver enzymes and lipid profile related to non-alcoholic fatty liver disease in adolescents with obesity. Nutr Health. 2017;23(4):281-8.

https://doi.org/10.1177/0260106017720350

Feng W, Gao C, Bi Y, Wu M, Li P, Shen S, et al. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. J Diabetes. 2017;9(8):800-9.

https://doi.org/10.1111/1753-0407.12555

Khoo J, Hsiang J, Taneja R, Law NM, Ang TL. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: a pilot randomized trial. Diabetes Obes Metab. 2017;19(12):1814-17.

https://doi.org/10.1111/dom.13007

Faludi A, Izar M, Saraiva J, Chacra A, Bianco H, Afiune Neto A, et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose: 2017. Arq Bras Cardiol. 2017;109(1):1-76.

https://dx.doi.org/10.5935/abc.20170121

Klebanoff MJ, Corey KE, Chhatwal J, Kaplan LM, Chung RT, Hur C. Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost-effectiveness analysis. Hepatology. 2017;65(4):1156-64.

https://doi.org/10.1002/hep.28958




DOI: https://doi.org/10.34119/bjhrv3n1-084

Refbacks

  • There are currently no refbacks.